PTN

Palatin is a pre-revenue obesity/melanocortin (MC4R) developer that has become a distressed shell in market terms. After selling its only commercial product, Vyleesi, to Cosette in December 2023, FY2025 revenue collapsed to $0.00 (from $4.49M in FY2024), so there is no operating business generating cash — only an R&D program spending $14.9M and burning $21.3M of operating cash for the year. Against that burn sits just $2.56M of cash (down 73% YoY) and $2.92M of current assets versus $8.01M of current liabilities. That is roughly six weeks of runway on the year's burn rate; the company cannot fund its pipeline without imminent, heavily dilutive financing, and stockholders' equity is already negative at -$4.78M (liabilities/equity of -1.68x is a red flag, not a valuation).

The filing corroborates the distress the numbers imply. The stock was pushed off NYSE American to the OTCQB in May 2025 and executed a 1-for-50 reverse split effective August 2025 — classic listing-rescue mechanics, not signs of strength. On September 19, 2025 there were only ~50 record holders and the non-affiliate market value was just $8.3M at $8.64. There is active litigation from H.C. Wainwright over allegedly owed warrants and damages tied to a January 2024 engagement, an overhang that could force more share issuance. Diluted EPS of -$32.15 and a -$459M accumulated deficit underscore that decades of spending have produced no self-sustaining product.